Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema
Purpose: The aim was to investigate the effect and underlying mechanism of anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) by optical coherence tomography angiography (OCTA).Methods: Twenty-five eyes in 18 treatment-naïve patients with DME were included. All eyes...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2021.791442/full |
| _version_ | 1818971375950364672 |
|---|---|
| author | Shiyue Qin Shiyue Qin Chaoyang Zhang Chaoyang Zhang Haifeng Qin Haifeng Qin Hai Xie Hai Xie Dawei Luo Dawei Luo Qinghua Qiu Qinghua Qiu Qinghua Qiu Kun Liu Kun Liu Jingting Zhang Jingting Zhang Guoxu Xu Jingfa Zhang Jingfa Zhang |
| author_facet | Shiyue Qin Shiyue Qin Chaoyang Zhang Chaoyang Zhang Haifeng Qin Haifeng Qin Hai Xie Hai Xie Dawei Luo Dawei Luo Qinghua Qiu Qinghua Qiu Qinghua Qiu Kun Liu Kun Liu Jingting Zhang Jingting Zhang Guoxu Xu Jingfa Zhang Jingfa Zhang |
| author_sort | Shiyue Qin |
| collection | DOAJ |
| description | Purpose: The aim was to investigate the effect and underlying mechanism of anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) by optical coherence tomography angiography (OCTA).Methods: Twenty-five eyes in 18 treatment-naïve patients with DME were included. All eyes were imaged by OCTA at baseline and 1 week after monthly intravitreal aflibercept injection (IAI). Visual acuity was measured as best corrected visual acuity (BCVA). Additional parameters were evaluated by OCTA, including central macular thickness (CMT), the number of hyperreflective foci (HRF), foveal avascular zone (FAZ), vessel density (VD) in the deep capillary plexus (DCP), the en-face area of cystoid edema in DCP segmentation, and subretinal fluid (SRF) height.Results: The mean time between baseline and final follow-up by OCTA was 79.24 ± 38.15 (range, 28–163) days. Compared with baseline, BCVA was increased significantly after the 3rd IAI, while CMT was decreased significantly from the 1st IAI. SRF height and the area of cystoid edema in DCP segmentation were decreased significantly after the 2nd IAI compared with baseline. The number of HRF was decreased significantly after the 1st IAI (8.87 ± 9.38) compared with baseline (11.22 ± 10.63). However, FAZ’s area and perimeter as well as VD in DCP showed no significant changes post-treatment.Conclusion: Anti-VEGF is effective in treating DME, improving visual acuity and decreasing macular edema. The decreased HRF indicates anti-inflammatory effects of aflibercept to deactivate retinal microglia/macrophages. The decreased cystoid edema and SRF height indicated improved drainage function of Müller glial cells and retinal pigment epithelium after IAI. |
| first_indexed | 2024-12-20T14:51:23Z |
| format | Article |
| id | doaj.art-239570cf1512491bbf1609bf99c75540 |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-12-20T14:51:23Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-239570cf1512491bbf1609bf99c755402022-12-21T19:36:56ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2021-12-011210.3389/fphys.2021.791442791442Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular EdemaShiyue Qin0Shiyue Qin1Chaoyang Zhang2Chaoyang Zhang3Haifeng Qin4Haifeng Qin5Hai Xie6Hai Xie7Dawei Luo8Dawei Luo9Qinghua Qiu10Qinghua Qiu11Qinghua Qiu12Kun Liu13Kun Liu14Jingting Zhang15Jingting Zhang16Guoxu Xu17Jingfa Zhang18Jingfa Zhang19Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Ophthalmology, Taizhou People’s Hospital, Taizhou, ChinaDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, Shanghai, ChinaNational Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, ChinaDepartment of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Ophthalmology, Changhai Hospital, Shanghai, ChinaDepartment of Regenerative Medicine, Tongji Eye Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Pharmacology, Tongji Eye Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, Shanghai, ChinaNational Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, ChinaDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, Shanghai, ChinaNational Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, ChinaDepartment of Ophthalmology, Shigatse People’s Hospital, Xizang, ChinaDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, Shanghai, ChinaNational Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, ChinaDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, Shanghai, ChinaNational Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, ChinaDepartment of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, Shanghai, ChinaNational Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, ChinaPurpose: The aim was to investigate the effect and underlying mechanism of anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) by optical coherence tomography angiography (OCTA).Methods: Twenty-five eyes in 18 treatment-naïve patients with DME were included. All eyes were imaged by OCTA at baseline and 1 week after monthly intravitreal aflibercept injection (IAI). Visual acuity was measured as best corrected visual acuity (BCVA). Additional parameters were evaluated by OCTA, including central macular thickness (CMT), the number of hyperreflective foci (HRF), foveal avascular zone (FAZ), vessel density (VD) in the deep capillary plexus (DCP), the en-face area of cystoid edema in DCP segmentation, and subretinal fluid (SRF) height.Results: The mean time between baseline and final follow-up by OCTA was 79.24 ± 38.15 (range, 28–163) days. Compared with baseline, BCVA was increased significantly after the 3rd IAI, while CMT was decreased significantly from the 1st IAI. SRF height and the area of cystoid edema in DCP segmentation were decreased significantly after the 2nd IAI compared with baseline. The number of HRF was decreased significantly after the 1st IAI (8.87 ± 9.38) compared with baseline (11.22 ± 10.63). However, FAZ’s area and perimeter as well as VD in DCP showed no significant changes post-treatment.Conclusion: Anti-VEGF is effective in treating DME, improving visual acuity and decreasing macular edema. The decreased HRF indicates anti-inflammatory effects of aflibercept to deactivate retinal microglia/macrophages. The decreased cystoid edema and SRF height indicated improved drainage function of Müller glial cells and retinal pigment epithelium after IAI.https://www.frontiersin.org/articles/10.3389/fphys.2021.791442/fulldiabetic macular edemaanti-VEGFOCT angiographyinflammationhyperreflective focicystoid edema |
| spellingShingle | Shiyue Qin Shiyue Qin Chaoyang Zhang Chaoyang Zhang Haifeng Qin Haifeng Qin Hai Xie Hai Xie Dawei Luo Dawei Luo Qinghua Qiu Qinghua Qiu Qinghua Qiu Kun Liu Kun Liu Jingting Zhang Jingting Zhang Guoxu Xu Jingfa Zhang Jingfa Zhang Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema Frontiers in Physiology diabetic macular edema anti-VEGF OCT angiography inflammation hyperreflective foci cystoid edema |
| title | Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema |
| title_full | Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema |
| title_fullStr | Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema |
| title_full_unstemmed | Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema |
| title_short | Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema |
| title_sort | hyperreflective foci and subretinal fluid are potential imaging biomarkers to evaluate anti vegf effect in diabetic macular edema |
| topic | diabetic macular edema anti-VEGF OCT angiography inflammation hyperreflective foci cystoid edema |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2021.791442/full |
| work_keys_str_mv | AT shiyueqin hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT shiyueqin hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT chaoyangzhang hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT chaoyangzhang hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT haifengqin hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT haifengqin hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT haixie hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT haixie hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT daweiluo hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT daweiluo hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT qinghuaqiu hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT qinghuaqiu hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT qinghuaqiu hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT kunliu hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT kunliu hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT jingtingzhang hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT jingtingzhang hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT guoxuxu hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT jingfazhang hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema AT jingfazhang hyperreflectivefociandsubretinalfluidarepotentialimagingbiomarkerstoevaluateantivegfeffectindiabeticmacularedema |